[
  {
    "ts": null,
    "headline": "Here’s What Analysts Are Saying About Bristol-Myers Squibb Company (BMY)",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best medical research stocks to buy according to hedge funds. Bernstein reiterated its Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) on February 10 and set a price target of $58.00. Bristol-Myers Squibb Company (NYSE:BMY) also received a rating update from Morgan Stanley on February 6, which lifted […]",
    "url": "https://finnhub.io/api/news?id=bb137a922c18ef6b9c000317a54ef1c59ba3e5e80a07be8868f876c814fc8073",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994658,
      "headline": "Here’s What Analysts Are Saying About Bristol-Myers Squibb Company (BMY)",
      "id": 139085086,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best medical research stocks to buy according to hedge funds. Bernstein reiterated its Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) on February 10 and set a price target of $58.00. Bristol-Myers Squibb Company (NYSE:BMY) also received a rating update from Morgan Stanley on February 6, which lifted […]",
      "url": "https://finnhub.io/api/news?id=bb137a922c18ef6b9c000317a54ef1c59ba3e5e80a07be8868f876c814fc8073"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Resets Pipeline With RNA Deals And Cost Focus",
    "summary": "Bristol-Myers Squibb (NYSE:BMY) has outlined a broad pipeline refresh that includes multiple recent product launches and the announcement of a new R&D facility. The company has agreed to acquire Orbital Therapeutics, expanding its presence in RNA based medicines. New collaborations with BioNTech and Philochem target next generation cancer and immunology treatments. Management has paired these moves with plans for major cost savings and added manufacturing capacity. Bristol-Myers Squibb,...",
    "url": "https://finnhub.io/api/news?id=a6ab617e7724ada414d1fdc7f7c0ce4a30785c4d5b232f8820670976b58b635b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770974337,
      "headline": "Bristol-Myers Squibb Resets Pipeline With RNA Deals And Cost Focus",
      "id": 139079180,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (NYSE:BMY) has outlined a broad pipeline refresh that includes multiple recent product launches and the announcement of a new R&D facility. The company has agreed to acquire Orbital Therapeutics, expanding its presence in RNA based medicines. New collaborations with BioNTech and Philochem target next generation cancer and immunology treatments. Management has paired these moves with plans for major cost savings and added manufacturing capacity. Bristol-Myers Squibb,...",
      "url": "https://finnhub.io/api/news?id=a6ab617e7724ada414d1fdc7f7c0ce4a30785c4d5b232f8820670976b58b635b"
    }
  }
]